Salix Pharma up 18% on positive trial results
Salix Pharmaceuticals Ltd. (Nasdaq:SLXP) rose by 18% this morning after the company announced positive clinical trial results from a study of Rifaximin, its potential treatment for irritable bowel syndrome.
The Orlando, Fla.-based pharmaceutical company said at 9:00 am ET that symptoms of patients treated with Rifaximin improved more than in patients treated with a placebo.
By midday the stock is at $6.74, up $1.06 from Friday’s close. Shares have traded as low as $5.34 and as high as $13.33 in the past year.
For detailed price information and news stories on Salix Pharmaceuticals, click SLXP.
About the Author
Contributing author Mary Ann Azevedo has more than 13 years of writing and editing experience that includes coverage of a broad range of companies.
Read More
(click a star)
Enter comment: